OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
An annual survey on inspections and audits has revealed opportunities to use more flexible approaches to optimize processes.
January 30, 2023
FDA plans to authorize a common bivalent shot that targets both the original COVID-19 strain and Omicron subvariants.
January 20, 2023
CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.
January 03, 2023
Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?
Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.
December 20, 2022
FDA has announced that bebtelovimab is not currently authorized for emergency use in any region of the US.
November 02, 2022
Industry and the government must work closely to ensure the UK remains a competitor in the clinical research field.
October 21, 2022
The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.
The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.
October 13, 2022
FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.
September 27, 2022
Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.